Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834584 | 0.75 | MAOA (0.45) | MEN1KMT2AMAOAMAOBATM | |
| SCHEMBL28220536 | 0.74 | NCF1 (0.47) | MEN1KMT2AMAOAGBA1LMNA | |
| SCHEMBL29632453 | 0.72 | MAOA (0.45) | MEN1KMT2AMAOAMAOBMAPT | |
| SCHEMBL7849358 | 0.70 | TLR8 (0.42) | MEN1KMT2AMAOAMAOBATM | |
| SCHEMBL26692293 | 0.68 | IDO1 (0.42) | MEN1KMT2AMAPT | |
| SCHEMBL3456970 | 0.67 | CXCR2 (0.41) | MEN1KMT2AMAOAMAOBLMNA | |
| SCHEMBL8397399 | 0.66 | MAOA (0.50) | MEN1KMT2AGRM2MAOAMAOB | |
| SCHEMBL24373921 | 0.64 | LMNA (0.42) | MAOAMAOBLMNAATMMAPT | |
| SCHEMBL27866901 | 0.64 | LMNA (0.39) | MEN1KMT2AMAOAMAOBGBA1 | |
| SCHEMBL2104448 | 0.63 | CES2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258688-B1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| CN-1951917-B | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2012-07-18 | — | — | CN | disclosed |
| EP-2258688-A1 | Pyridinone derivatives for treatment of atherosclerosis | SmithKline Beecham Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| CN-1951917-A | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-04-25 | — | — | CN | disclosed |
| CN-1280275-C | Pyridone derivatives for the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2006-10-18 | — | — | CN | disclosed |
| US-20050245552-A1 | N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
| EP-1492787-A2 | (CONDENSED) PYRIMIDONE AND (CONDENSED) PYRIDONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| EP-1492533-A1 | N-SUBSTITUTED PYRIDINONE AND PYRIMIDINONE DERIVATIVES FOR USE AS LP-PLA2 INHIBITORS IN THE TREATMENT OF ARTHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| US-20040063753-A1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-01 | — | — | US | disclosed |
| CN-1479724-A | Pyridone derivatives for the treatment of atherosclerosis | ʷ��˿�������ȳ�ķ����˾ | 2004-03-03 | — | — | CN | disclosed |
| WO-2003086400-A1 | N-SUBSTITUTED PYRIDINONE AND PYRIMIDINONE DERIVATIVES FOR USE AS LP-PLA2 INHIBITORS IN THE TREATMENT OF ARTHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087088-A2 | (CONDENSED) PYRIMIDONE AND (CONDENSED) PYRIDONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326841-A1 | PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SmithKline Beecham P.L.C. (GB) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030904-A1 | PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLA2G7, PLA2G4B | SOS1 3631/4885MEN1 3563/4885KMT2A 3439/4885 |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, PLA2G12A, ENPP2 | SOS1 3385/4885MEN1 2539/4885KMT2A 2447/4885 |
| US-20040063753-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLPBP, PLAA | SOS1 3250/4885MEN1 4202/4885KMT2A 4096/4885 |
| US-20050245552-A1 | N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis | PLA2G12A, PLA2G4B, PLA2G1B | SOS1 3133/4885MEN1 2281/4885KMT2A 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.